Table 1.

Demographic characteristics of each patient in the FAERS database from January 2004 to March 2023.

	Voriconazole	Levodopa	Risperidone	Chlorpromazine	Voriconazole  + Levodopa	Voriconazole  + Risperidone	Voriconazole  + Chlorpromazine
Sex, n (%)
Female	7858 (34.4)	37,049 (40.8)	34,419 (31.4)	2712 (42.1)	8 (40.0)	41 (49.4)	18 (69.2)
Male	12,313 (53.9)	48,525 (53.4)	63,699 (58.0)	3143 (48.8)	11 (55.0)	35 (42.2)	7 (26.9)
Unknown	2668 (11.7)	5236 (5.8)	11,639 (10.6)	580 (9.0)	1 (5.0)	7 (8.4)	1 (3.8)
Age (years)
Median [IQR]	57 [36–68]	73 [66–79]	41 [23–60]	47 [33–61]	75 [69–79]	66 [38–66]	41 [18–51]
Unknown, n (%)	4669 (20.4)	32,272 (35.5)	46,174 (42.1)	1302 (20.2)	1 (5.0)	12 (14.5)	1 (3.8)
Weight (kg)
Medican [IQR]	64.0 [50.4–79.0]	70.3 [59.0–83.0]	75.0 [60.0–93.0]	70.0 [55.2–86.0]	83.9 [59.5–87.3]	49.0 [18.5–63.0]	53.0 [32.0–65.3]
Unknown, n (%)	16,581 (72.6)	68,060 (74.9)	86,925 (79.2)	4523 (70.3)	13 (65.0)	63 (75.9)	15 (57.7)
Country, n (%)
United States	8729 (38.2)	45,740 (50.4)	62,347 (56.8)	1,978 (30.7)	8 (40.0)	39 (47.0)	9 (34.6)
France	2155 (9.4)	3389 (3.7)	6755 (6.2)	887 (13.8)	0 (0.0)	3 (3.6)	6 (23.1)
United Kingdom	1442 (6.3)	2804 (3.1)	5961 (5.4)	616 (9.6)	0 (0.0)	0 (0.0)	1 (3.8)
Germany	548 (2.4)	5773 (6.4)	4985 (4.5)	19 (0.3)	0 (0.0)	1 (1.2)	1 (3.8)
Japan	2426 (10.6)	3333 (3.7)	4623 (4.2)	726 (11.3)	5 (25.0)	12 (14.5)	2 (7.7)
Canada	543 (2.4)	1511 (1.7)	3691 (3.4)	261 (4.1)	0 (0.0)	2 (2.4)	0 (0.0)
Italy	518 (2.3)	2702 (3.0)	2546 (2.3)	447 (6.9)	0 (0.0)	1 (1.2)	0 (0.0)
Spain	633 (2.8)	2478 (2.7)	1450 (1.3)	48 (0.7)	0 (0.0)	19 (22.9)	0 (0.0)
Netherlands	444 (1.9)	2075 (2.3)	804 (0.7)	56 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)
Australia	388 (1.7)	1339 (1.5)	1224 (1.1)	217 (3.4)	0 (0.0)	0 (0.0)	0 (0.0)
Others	4033 (17.7)	9503 (10.5)	10,112 (9.2)	728 (11.3)	7 (35.0)	3 (3.6)	4 (15.4)
Unknown	980 (4.3)	10,163 (11.2)	5259 (4.8)	452 (7.0)	0 (0.0)	3 (3.6)	3 (11.5)

Data are presented as medians [IQRs]. IQR, interquartile range.